Joan Maurel, MD PhD, trained in Medical Oncology in 1995 at the Germans Trias y Pujol University Hospital under the supervision of Prof. Rafael Rosell. Germans Trias y Pujol. From 1997 to 1999 he worked as Medical Oncologist at Miguel Servet University Hospital. Since January 2000 he has been working at the Hospital Clínic de Barcelona focusing on Gastrointestinal Cancer. He is a Senior Consultant of the Department of Medical Oncology, member of the Center for Biomedical Research Network in Liver and Digestive Diseases (CIBEREHD), member of the Translational Genomics and Targeted Therapies in Solid Tumors Group (IDIBAPS) and former president of the GEMCAD Cooperative Group.

He has focused his research on understanding the biological and clinical diversity of human tumors, guiding the design of clinical trials and the development of biomarkers to identify optimal therapies in patients with colorectal cancer. He has led more than 20 prospective academic clinical trials in Gastrointestinal cancers and sarcomas. He has recently led two immunotherapy trials evaluating the efficacy of autologous tumor lysate dendritic dendritic vaccine (ALDV) (alone-NCT01413295) or ALDV associated with avelumab (NCT03152565). Finally, he has coordinated the largest clinical trial conducted in metastatic colorectal cancer in Spain (GEMCAD 14-01-NCT02254941) with a total of 1108 patients, included from June 2014 to June 2018. This trial evaluates the benefit of early versus deferred use of monoclonal antibodies in mCRC.

It has received several competitive grants including FIS 2013 (PI/01728), FIS 2019 (PI19/00740). On the other hand, he has obtained private funding as Coordinator leading multiple prospective studies in colorectal cancer such as GEMCAD 09-03, GEMCAD 10-02, GEMCAD 10-03, GEMCAD 14-01, GEMCAD 16-02, GEMCAD 18-02 and GEMCAD 22-01. The total fund of all these studies amounts to almost 2M €. He led the colorectal area in the Translational Genomics and Targeted Therapies team in Solid Tumors at IDIBAPS. Currently this group is positioned in first place in IDIBAPS.

He presents currently more than 180 articles with a global impact factor in 2023 of 1,3M